Search peptides — top sellers first
Search peptides — top sellers first
Search peptides — top sellers first
Two incretin pathways, one molecule, deeper metabolic shifts
Made in USA — Synthesized in our cGMP-compliant US facility
Buy 1, Get 1 Free · auto-applied
Add 2+ items to cart to activate the discount
Secure, encrypted checkout
Frequently bought together
Researchers usually add these to complete the protocol.
BAC Water · 3ml
Essential · extras
GHK-CU · 50mg
recovery
Melanotan 2 · 10mg
Tanning
GLP-2-TZ · 30mg
Certificate of analysis
We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.
Freedom Diagnostics
Independent analytical lab
Certificate of Analysis
RESULT · PASS
Analytical results
HPLC Chromatogram
Main peak 99.61% · other 0.39%
Alex Johnson
Principal Chemist
Scanned 34×
Know your compound
GLP-2-TZ is a research compound that switches on two hormone receptors at once — GIP and GLP-1 — which together help control blood sugar and appetite signaling. Most earlier research molecules only hit one of these pathways.
Hitting both incretin receptors in parallel moves metabolic markers further than single-pathway compounds, and that's what made it the new reference point in the field. As the first dual-incretin agonist to reach late-stage study, it's become a benchmark researchers measure newer compounds against.
For research use only — not for human or veterinary use.
The research
The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.
In preclinical work, GLP-2-TZ was designed to switch on two incretin receptors at once — the GIP and GLP-1 receptors — the first dual-incretin approach to reach late-stage study.
GIP + GLP-1 engaged
Dual-incretin agonist mechanism
Across late-stage clinical research, HbA1c — the standard long-term blood-sugar marker — fell relative to baseline, though a fixed magnitude was not established here.
Directional reduction; exact magnitude not fixed
In metabolic research cohorts, lipid markers shifted in a favorable direction versus baseline, pointing to a broader metabolic effect.
Directional improvement; magnitude not quantified
In the same metabolic cohorts, blood-pressure markers trended lower than baseline, adding to the compound's metabolic profile.
Directional reduction; exact magnitude not fixed
Mechanism
A dual-incretin research peptide studied for hitting two metabolic receptors in parallel.
Glucagon-like peptide-1 signalling is studied for glucose-dependent insulin release and appetite regulation.
Glucose-dependent insulinotropic polypeptide is investigated for insulin sensitivity and nutrient handling.
The paired receptor action is researched for combined effects on blood sugar, lipids and body weight.
For research use only. Mechanisms described reflect published research literature.
The process
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
COA published
The certificate is posted to the open library, by lot, before the vial ships.
Best sellers
FAQ
Common questions about GLP-2-TZ
The COA guarantee
Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.
Order with coverThird-party tested
An independent, accredited lab — no commercial interest in the result.
A COA on every lot
A lot-specific certificate ships with each vial, archived by batch.
Test it yourself → refund
Re-test any batch at any lab. A mismatch is a full refund.
